Aster Insights
Matthew Pement is an experienced Scrum Master currently working at M2GEN since July 2022 and previously at Nike from January 2015 to July 2022, where Matthew led a multi-year project to enhance ecommerce search capabilities using Elasticsearch on AWS. Prior to Nike, Matthew served as Scrum Master III at Viewpoint Construction Software, focusing on improving team Scrum maturity and resolving conflicts. Matthew began their career in software development at Insight Distribution Software, where valuable Agile practices were explored, and held earlier positions in mobile application development and quality assurance. Matthew's background includes hands-on experience in technical roles and leadership in the US Army as a tank commander. Education includes studies at Oregon Institute of Technology and Portland Community College.
This person is not in any offices
Aster Insights
We believe that personalized medicine starts with a complete view of an individual across their lifetime. Our company was founded in 2006 on the unique principle that informed consent from patients entrusting us with a lifetime connection to their health information, paired with deep partnerships across academia and the life sciences industry, would unlock critical advances in curing cancer. Aster Insights leads the Oncology Research Information Exchange Network (ORIEN®), a consortium of the nation’s leading academic cancer centers that conduct Total Cancer Care®, the world’s largest and longest running observational research study in oncology. TCC® serves as the foundation for novel insights that power oncology breakthroughs. As a long-time innovator in oncology, Aster Insights has world-class expertise in accelerating the life cycle of oncology medical product development. Our solutions are based on scientific and clinical intelligence and strengthened by our unique partnership with patients, academia, and industry. We empower our partners to uncover new targets and biomarkers, enhance cancer detection, deepen our understanding of new treatments, discover new indications, and accelerate clinical trials. Together, we are changing the way cancer is studied, treated, and prevented.